IMRT

Synopsis

Nothing is clear for low risk CAP

High doses are needed to control intermediate and high dose CAP

The role of adjuvant pelvic RT is unclear

RT of manifest LN-Metastases is being evaluated, impact on therapy-free interval or survival is unclear

Salvage RT results in >>50% secondary biochemical relapse free survival and ~50% long term OS

Hypofractionation is gaining traction, initial results are encouraging, tight margins are neede to control toxicity, We may have to rethink dose volume constraints

Name I Folie 1 I Datum